Merck Acquires $2 Billion Licensing Deal from Hengrui: Transforming Lp(a) from "Genetic Destiny" to "Treatable Disorder"

Lp(a): The Overlooked Code of Cardiovascular Risk

Lp(a), the abbreviated form of lipoprotein(a), represents a distinctive atherogenic lipoprotein particle. This macromolecular complex consists of apolipoprotein B-100 covalently linked to apolipoprotein(a) via a disulfide bond. While structurally homologous to low-density lipoprotein (LDL), its unique pathogenicity stems from the characteristic multikringle-domain apolipoprotein(a) moiety.

Genetic Determinants

Lp(a) levels exhibit >1000-fold interindividual variability, with >90% heritability determined by the LPA gene locus. Notably, these concentrations remain unaffected by dietary modifications or exercise interventions.

Lp(a) exerts combined atherogenic and thrombogenic effects:

LDL-like cholesterol deposition in vascular walls

Direct impairment of fibrinolysis through structural mimicry of plasminogen

Molecular Pathogenesis: Precision Strikes from Molecules to Vasculature

Fibrinolytic System Inhibition

Lp(a)'s structural homology with plasminogen (PLG) enables competitive binding to fibrin sites, forming quaternary complexes (t-PA-plasminogen-fibrin-Lp(a)) that reduce fibrinolytic efficiency by >80%, significantly impeding thrombus resolution.

Inflammatory Amplification

The LDL moiety carries oxidized phospholipids (oxPL) that activate endothelial proinflammatory pathways, accelerating atherosclerotic plaque formation.

Coagulation Cascade Activation

Enhances platelet aggregation (2-3-fold increased sensitivity to thrombin receptor agonists)

Inactivates tissue factor pathway inhibitor (TFPI), elevating thrombotic risk by 40%

Therapeutic Revolution: From Intractable to Targetable

Emerging Targeted Therapies

Small Molecule Inhibitors:

HRS-5346 (Hengrui/Merck): Oral administration demonstrating 85% Lp(a) reduction in Phase II trials (12 weeks), potentially becoming the first oral Lp(a) inhibitor.

Muvalaplin (Eli Lilly): Blocks Apo(a)-ApoB interaction with once-daily dosing, achieving 85.8% reduction.

Antisense Oligonucleotides (ASO):

Pelacarsen: Reduces Lp(a) by 98% through Apo(a) mRNA suppression, with Phase III data showing 30% cardiovascular event reduction.

Olpasiran: Subcutaneous quarterly injections sustain >90% Lp(a) reduction for 48 weeks.

Gene Editing Advancements

CRISPR Therapeutics' CTX320 demonstrates 94% Lp(a) reduction persisting to 224 days post-single infusion via hepatic Apo(a) gene knockout, currently in Phase I trials.

Clinical Strategy: Three Proactive Approaches

High-Risk Population Screening

Routine testing for:

Familial hypercholesterolemia (FH) patients

Those with premature CAD family history

Recurrent cardiovascular event sufferers

Intervention thresholds: >50 mg/dL (actionable), >150 mg/dL (extreme risk)

Multidisciplinary Management

Cardiology: Novel targeted agents for optimized lipid profiles

Genetic counseling: Familial cascade screening for significant Lp(a) elevation

Future Directions

Combination therapies: ASO + PCSK9 inhibitors for dual Lp(a)/LDL-C reduction

Predictive modeling: Lp(a)-based atherosclerosis progression algorithms

Conclusion

The discovery of Lp(a) unveiled cardiovascular disease's "genetic dark matter." With oligonucleotide therapies and small molecule inhibitors now emerging, this once "untreatable" risk factor approaches a therapeutic inflection point. Through early screening and precision interventions, we may ultimately overcome genetic determinism in cardiovascular health.

Recommended Product

Lp(a) His Tag Protein, Human

Catalog No.: UA011166

>95% by SDS-PAGE & >90% by SEC-HPLC

Click on the product catalog numbers below to access detailed information on our official website.